Literature DB >> 24184114

Tapping the treasure of intracellular oncotargets with immunotherapy.

Cheng William Hong1, Qi Zeng2.   

Abstract

It is commonly believed that antibodies are too large (∼150 kDa) to access the intracellular compartment. Therefore, therapeutic antibodies have been traditionally used to target cell surface receptors or soluble proteins in the circulation, leaving a large intracellular treasure of potential cancer-specific targets untapped. This review offers new perspectives on our recently proposed concept that antibodies can be used to target intracellular tumor antigens for anti-cancer therapy. We propose to vastly expand the repertoire of potential targets for cancer immunotherapy since many excellent cancer targets are inside cells.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody therapy; Cancer; Extracellular receptor; Immunotherapy; Intracellular oncotarget; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 24184114     DOI: 10.1016/j.febslet.2013.10.025

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Authors:  Anne Montfort; Oliver Pearce; Eleni Maniati; Benjamin G Vincent; Lisa Bixby; Steffen Böhm; Thomas Dowe; Edmund H Wilkes; Probir Chakravarty; Richard Thompson; Joanne Topping; Pedro R Cutillas; Michelle Lockley; Jonathan S Serody; Melania Capasso; Frances R Balkwill
Journal:  Clin Cancer Res       Date:  2016-06-27       Impact factor: 12.531

Review 2.  Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

Authors:  Vladimir L Gabai; Victor I Shifrin
Journal:  Int Rev Immunol       Date:  2014-10       Impact factor: 5.311

3.  PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Authors:  Min Thura; Abdul Qader Al-Aidaroos; Abhishek Gupta; Cheng Ean Chee; Soo Chin Lee; Kam Man Hui; Jie Li; Yeoh Khay Guan; Wei Peng Yong; Jimmy So; Wee Joo Chng; Chin Hin Ng; Jianbiao Zhou; Ling Zhi Wang; John Shyi Peng Yuen; Henry Sun Sien Ho; Sim Mei Yi; Edmund Chiong; Su Pin Choo; Joanne Ngeow; Matthew Chau Hsien Ng; Clarinda Chua; Eugene Shen Ann Yeo; Iain Bee Huat Tan; Joel Xuan En Sng; Nicholas Yan Zhi Tan; Jean Paul Thiery; Boon Cher Goh; Qi Zeng
Journal:  Nat Commun       Date:  2019-06-06       Impact factor: 14.919

Review 4.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04

Review 5.  Survivin: a unique target for tumor therapy.

Authors:  Himani Garg; Prerna Suri; Jagdish C Gupta; G P Talwar; Shweta Dubey
Journal:  Cancer Cell Int       Date:  2016-06-23       Impact factor: 5.722

Review 6.  Intracellular targeting with engineered proteins.

Authors:  Shane Miersch; Sachdev S Sidhu
Journal:  F1000Res       Date:  2016-08-10

7.  RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Authors:  Laura Mandik-Nayak; James B DuHadaway; Jennifer Mulgrew; Elizabeth Pigott; Kaylend Manley; Summer Sedano; George C Prendergast; Lisa D Laury-Kleintop
Journal:  Dis Model Mech       Date:  2017-09-07       Impact factor: 5.758

8.  Elevated Autoantibodies in Subacute Human Spinal Cord Injury Are Naturally Occurring Antibodies.

Authors:  Angel Arevalo-Martin; Lukas Grassner; Daniel Garcia-Ovejero; Beatriz Paniagua-Torija; Gemma Barroso-Garcia; Alba G Arandilla; Orpheus Mach; Angela Turrero; Eduardo Vargas; Monica Alcobendas; Carmen Rosell; Maria A Alcaraz; Silvia Ceruelo; Rosa Casado; Francisco Talavera; Ramiro Palazón; Nuria Sanchez-Blanco; Doris Maier; Ana Esclarin; Eduardo Molina-Holgado
Journal:  Front Immunol       Date:  2018-10-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.